You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 259 No. 13, April 1, 1988 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Nosocomial Aseptic Meningitis Associated With Administration of OKT3

Michael A. Martin, MD; R. Michael Massanari, MD; Dai D. Nghiem, MD; John L. Smith, MD; Robert J. Corry, MD

JAMA. 1988;259(13):2002-2005.


Abstract

An outbreak of nosocomial aseptic meningitis involving four renal allograft recipients on the transplant service occurred in July 1986, shortly after the release of the murine monoclonal antibody OKT3 for therapy for acute allograft rejection. No bacteria, fungi, or viruses were isolated from cultures of the cerebrospinal fluid of the four patients. All four had acute allograft rejection treated with OKT3 and developed signs and/or symptoms of meningitis within 72 hours of receiving the drug. To identify potential risk factors, the four patients with aseptic meningitis were compared with 12 patients on the renal transplant service in July 1986 who did not have signs or symptoms of meningitis. The development of aseptic meningitis was strongly associated with administration of OKT3. Because of this association, prospective surveillance of meningitis in patients receiving OKT3 was instituted. From November 1986 to May 1987, three (14%) of 21 patients treated with OKT3 developed aseptic meningitis. The clinical course of aseptic meningitis associated with OKT3 appears to be benign and self-limited. Nonetheless, this observation warrants continued surveillance of OKT3 therapy.

(JAMA 1988;259:2002-2005)



Author Affiliations

From the Departments of Medicine (Drs Martin and Massanari) and Surgery (Drs Nghiem, Smith, and Corry), University of Iowa College of Medicine, Iowa City. Dr Nghiem is now with the Allegheny General Hospital, Pittsburgh.


Footnotes

Reprint requests to The University of Iowa Hospitals and Clinics, C-41, GH, Iowa City, IA 52242 (Dr Martin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Muromonab-CD3--Induced Neurotoxicity: Report of Two Siblings, One of Whom Had Subsequent Cyclosporin-Induced Neurotoxicity
Thaisetthawatkul et al.
J Child Neurol 2001;16:825-831.
ABSTRACT  

The Challenge of Drug-Induced Aseptic Meningitis
Moris and Garcia-Monco
Arch Intern Med 1999;159:1185-1194.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.